Editorial of special column on Drug targets and drug development for Alzheimer's disease

作     者：Wen-Xing Ding Russell H.Swerdlow 

作者机构：Department of PharmacologyToxicology and TherapeuticsDepartment of Internal Medicinethe University of Kansas Medical CenterKansas CityKS 66160USA Department of Neurologythe University of Kansas Medical CenterKansas CityKS 66160USA 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2022年第12卷第4期

页      面：1686-1687页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：This study was supported in part by the National Institutes of Health(NIH,USA)fund R01 AG072895(WXD) P30 AG072973(RHS) 

主　　题：Alzheimer metabolism inflammation 

摘      要：Alzheimer s disease(AD)is the most common form of progressive dementia in people aged 65 years and *** major pathological features of AD are the accumulation of extracellularβ-amyloid plaques and intracellular neurofibrillary tangles composed of aggregated,hyperphosphorylated *** addition to an accumulation of protein aggregates,mitochondrial dysfunction,altered lipid metabolism and increased neuroinflammation also play critical roles in the pathogenesis of AD and its associated dementia.